Two new indications approved for Cosentyx

The licensed indications for Cosentyx (secukinumab) have been extended to include the treatment of active psoriatic arthritis in patients with an inadequate response to DMARD therapy and the treatment of active ankylosing spondylitis in patients with an inadequate response to conventional therapy.

The interleukin-17A-targeting antibody is licensed for use as monotherapy in both indications and in psoriatic arthritis may also be used in combination with methotrexate.

Cosentyx remains licensed for use in the treatment of moderate to severe plaque psoriasis.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases